Are synthetic peptides real toxic allergens? a comprehensive literature review and update on therapeutic and adverse toxic immunogenic potentials of peptides -truth or dare

  • Authors

    • Sahar Y. Issa DR. SAHAR YOUNES IBRAHIM ISSALECTURER FORENSIC MEDICINE & CLINICAL TOXICOLOGY-FACULTY OF MEDICINE-ALEXANDRIA UNIVERSITYConsultant Toxicologist & head of Toxicology Department DPCCemail: syissa@moh.gov.saMobile Phone: +2011142490525 http://orcid.org/0000-0001-5432-5028
    • R. Carmichael Helix Biomedix
    2020-03-06
    https://doi.org/10.14419/ijpt.v8i1.30275
  • Mutagenicity, Peptides, Skincare Products, Amino Acids, Skin.

  • Abstract

    In the pharmaceutical industry, there is much debate about how to translate current guidelines on biotherapeutic immunogenicity testing into a real-life strategy that meets the regulatory requirements of newly discovered pharmaceutical peptides. This paper will present a consensus view on the essential elements for biotherapeutic immunogenicity consideration for pharmaceutical synthetic peptides to ensure patient safety and allow successful market entry. This paper's scope is limited to aspects relevant to the biotherapeutic synthetic peptide pharmaceuticals and does not include necessary academic immunogenicity studies. Medical research shows little support for antigenic or allergic reactions to short synthetic peptides. These negligible results warranted a detailed literature review to examine antigens and allergens linked to peptides.

     

  • References

    1. [1] A. Zimmerman, L. Bai, D.D. Ginty. (2014): The gentle touch receptors of mammalian skin, Science 346 (6212), 950- 4. https://doi.org/10.1126/science.1254229.

      [2] A.A. Romanovsky (2014): Skin temperature: its role in thermoregulation, Acta Physiol 210 (3) (March 2014) 498-507. https://doi.org/10.1111/apha.12231.

      [3] Ahn MH, Park BJ, and Kwon JH, et al. (2008): Asp-Tyr-Leu-Lys tetrapeptide inhibits airway inflammation in toluene-2,4-diisocyanate-induced asthma mice. Clin Exp Allergy 2008 Jun; 38(6):1025-32. https://doi.org/10.1111/j.1365-2222.2008.02977.x.

      [4] Berger, C. and Niesner, U. (2011): Immunogenicity of microbial digestive enzymes for oral replacement therapy in pancreatic exocrine insufficiency. In: Tovey, M.G. (Ed.), Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. John Wiley & Sons, Inc., Hoboken, NJ, USA. https://doi.org/10.1002/9781118075685.ch20.

      [5] Bhogal, N. (2010): Immunotoxicity and immunogenicity of biopharmaceuticals: design concepts and safety assessment. Curr. Drug Saf. 5, 293. https://doi.org/10.2174/157488610792246037.

      [6] Briner TJ, Kuo M-C, Keating KM, et al. (1993): Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci- U S A, 90:7608–7612. https://doi.org/10.1073/pnas.90.16.7608.

      [7] Buttel, I.C., Voller, K., Schneider, C.K. (2010): Immunogenicity and its impact on benefit/risk considerations in the authorization of biopharmaceuticals. Curr. Drug Saf. 5, 287-11 https://doi.org/10.2174/157488610792245993.

      [8] C.C. Udenigwe (2014): Bioinformatics approaches prospects and challenges of food bioactive peptide research, Trends Food Sci. Technol. 36:137-143. https://doi.org/10.1016/j.tifs.2014.02.004.

      [9] Campbell JD, Buckland KF, McMillan SJ, et al. (2009): Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med, 206:1535. https://doi.org/10.1084/jem.20082901.

      [10] Casadevall N., Nataf J., and Viron B., et al. (2002): Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346-469. https://doi.org/10.1056/NEJMoa011931.

      [11] Cathelijne Kloks, Claudia Berger, Pierre Cortez et al. (2015): A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective. Journal of Immunological Methods 417: 1–9 https://doi.org/10.1016/j.jim.2015.01.003.

      [12] Coiffier B., Lepretre S. and Pedersen L.M et al. (2008): Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1- 2 study. Blood 1011- 94. https://doi.org/10.1182/blood-2007-09-111781.

      [13] Cosmetic Ingredient Review expert panel (2014): 131st Meeting findings. June 9-10, 2014. Accessed online, 27th December 2019.

      [14] D. Agyei, and M.K. Danquah (2011): Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides, Biotechnol. Adv. 29: 272-7. https://doi.org/10.1016/j.biotechadv.2011.01.001.

      [15] Daniel A.B, Strickland J, and Allen D, et al. (2018): International regulatory requirements for skin sensitization testing. Regul Toxicol Pharmacol, 95:52-65. https://doi.org/10.1016/j.yrtph.2018.03.003.

      [16] Frisch B, Muller S, and Briand JP et al. (1991): Parameters affecting the immunogenicity of a liposome-associated synthetic hexapeptide antigen. Eur J Immunol. 1991 Jan; 21(1):185-93. https://doi.org/10.1002/eji.1830210128.

      [17] Getts, D.R., Getts, M. T., McCarthy, D.P. et al. (2010): Have we overestimated the benefit of human(ized) antibodies?. MAbs; 2(6): 682– 94. https://doi.org/10.4161/mabs.2.6.13601.

      [18] Goldsby, R.A., Kindt T.J., and Osborne, B.A. (2000): T-cell maturation and the thymus, in Immunology, 4th ed, Ch. 10, pp. 239–67 (NewYork, W. H. Freeman Company).

      [19] Gregoriadis G., Sanjay Jain, and Ioannis Papaioannouet al., (2005): Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm. 300 (1–2), 125– 30. https://doi.org/10.1016/j.ijpharm.2005.06.007.

      [20] H. Kojima. (2017): Safety Assessment of Cosmetic Ingredients. National Institute of Health Sciences (NIHS), Tokyo, Japan. Cosmetic Science and Technology: Theoretical Principles and Applications. (Chapter 51): 793-803. https://doi.org/10.1016/B978-0-12-802005-0.00051-3.

      [21] Harris, R.C. Hoffman JR, Allsopp A, Routledge NB. (2012): L-Glutamine absorption is enhanced after the ingestion of alanyl-glutamine compared with the free amino acid or wheat protein. Nutr. Res. 32 (4), 272– 7. https://doi.org/10.1016/j.nutres.2012.02.003.

      [22] I.C. Büttel, P. Chamberlain, Y. Chowers et al. (2011): Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39;100 -109. https://doi.org/10.1016/j.biologicals.2011.01.006.

      [23] K. Fosgerau and T. Hoffmann (2015): Peptide therapeutics: current status and future directions, Drug Discov. Today 20: 122-128. https://doi.org/10.1016/j.drudis.2014.10.003.

      [24] Kimber I, Dearman RJ, Scholes EW, et al. (1994): The local lymph node assay: developments and applications. Toxicology: (93):13–31. https://doi.org/10.1016/0300-483X(94)90193-7.

      [25] Kovalainen, M., Mönkäre J, and Riikonen J. et al. (2015): Novel delivery systems for improving the clinical use of peptides. Pharmacol. Rev. 7, 541–61. https://doi.org/10.1124/pr.113.008367.

      [26] Larche M and Moldavar D: (2011): Immunotherapy with Peptides. Allergy, 66:784–791. https://doi.org/10.1111/j.1398-9995.2011.02610.x.

      [27] Larche M: (2007): Immunotherapy with Allergen Peptides. Allergy Asthma Clin Immunol, 3:53–59. https://doi.org/10.1186/1710-1492-3-2-53.

      [28] Lau, J. L., and Dunn, M. K. (2017): Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions. Bioorg. Med. Chem, https://doi.org/10.1016/j.bmc.2017.06.052.

      [29] Li, J., Yang, C., Xia, Y., et al. (2001): Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98, 3241. https://doi.org/10.1182/blood.V98.12.3241.

      [30] Lian Q. Jiang W and Cheng Y et al. (2015): A novel pentapeptide originated from calf thymus named TIPP shows an inhibitory effect on lung allergic inflammation. Int Immunopharmacol. 2015 Feb;24(2):256-266. https://doi.org/10.1016/j.intimp.2014.12.019.

      [31] M.Z. Albanna, I.V.J.H. Holmes, and J. Fenner (2016): Clark, Anatomy, Physiology, Histology, and Immunohistochemistry of Human Skin. Skin Tissue Engineering and Regenerative Medicine, Academic Press, pp. 1-17. https://doi.org/10.1016/B978-0-12-801654-1.00001-2.

      [32] Madsbad, S. (2016): Review of Head-to-Head Comparisons of Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Obes. Metab, 18(4), 317–332. https://doi.org/10.1111/dom.12596.

      [33] Mathison R, Lo P, and Moore G, et al. (1998): Attenuation of intestinal and cardiovascular anaphylaxis by the salivary gland tripeptide FEG and its D-isomeric analog feG. Peptides;19(6):1037-42. https://doi.org/10.1016/S0196-9781(98)00048-5.

      [34] Mathison RD, Befus AD, and Davison JS. (1997): A novel submandibular gland peptide protects against endotoxic and anaphylactic shock. Am J Physiol. Sep;273(3 Pt 2): R1017-23. https://doi.org/10.1152/ajpregu.1997.273.3.R1017.

      [35] McGregor, D.P. (2008): Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 8 (5), 616 – 9. https://doi.org/10.1016/j.coph.2008.06.002.

      [36] McNeil, B. D.; Pundir, P.; Meeker, S. et al. (2015): Identification of a Mast-Cell-Specific Receptor Crucial for Pseudo-Allergic Drug Reactions. Nature, 519(7542), 237–241. https://doi.org/10.1038/nature14022.

      [37] Niebecker, R. and Kloft, C. (2010): Safety of therapeutic monoclonal antibodies. Curr. Drug Saf. 5, 275. https://doi.org/10.2174/157488610792246055.

      [38] Norman PS, Ohman JL Jr, Long AA, et al. (1996): Treatment of cat allergy with T cell epitope containing peptides. Am J Respir Crit Care Med, 154:1623 – 8. https://doi.org/10.1164/ajrccm.154.6.8970345.

      [39] P. Vlieghe, V. Lisowski, J. Martinez, et al. (2010): Synthetic therapeutic peptides: science and market, Drug Discov. Today 15: 40-56. https://doi.org/10.1016/j.drudis.2009.10.009.

      [40] Pan, H., Ivashyna O, Sinha B. et al. (2011): Post-formulation peptide drug loading of nanostructures for metered control of NF kappa B signaling. Biomaterials 32 (1), 231– 8. https://doi.org/10.1016/j.biomaterials.2010.08.080.

      [41] Peter Socrates Creticos. (2014): Advances in synthetic peptide immuno-regulatory epitopes. Creticos World Allergy Organization Journal, 7-30. https://doi.org/10.1186/1939-4551-7-30.

      [42] Prenner BM. (1987): Double-blind placebo-controlled trial of intranasal IgE pentapeptide. Ann Allergy. May; 58(5):332-5.

      [43] R. Lax, C. Meenan (2012): Challenges for therapeutic peptides part 1: on the inside, looking out, Innov. Pharm. Pharmaceut. Technol. 42: 54- 6.

      [44] Sarmadi, B.H., Ismail, A., (2010): Antioxidative peptides from food proteins: a review. Peptides 31 (10), 1949–1956. https://doi.org/10.1016/j.peptides.2010.06.020.

      [45] Sato, A.K., Viswanathan M, Kent RB, et al., (2006): Therapeutic peptides: technological advances driving peptides into development. Curr. Opin. Biotech. 17 (6), 638–642. https://doi.org/10.1016/j.copbio.2006.10.002.

      [46] Schellekens, H., and Casadevall, N., (2004): Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 251 (Suppl. 2), ii4. https://doi.org/10.1007/s00415-004-1202-9.

      [47] Singh R. Nath A, and Gupta PP, et al. (2001): Antiallergic/antiasthmatic effect of novel antiallergic hexapeptide-95/220 in various experimental models. Indian J Exp Biol. Sep;39(9):871-7.

      [48] Tanabe S. (2007): Epitope peptides and immunotherapy. Curr Protein Pept Sci. Feb;8(1):109-18. https://doi.org/10.2174/138920307779941569.

      [49] Uhlig, T., ThemisKyprianou, Filippo Giancarlo Martinelli et al. (2014): The emergence of peptides in the pharmaceutical business: from exploration to exploitation. EuPA Open Proteom. 4, 1–12. https://doi.org/10.1016/j.euprot.2014.05.003.

      [50] Verhoef A, Alexander C, Kay AB, Larche M (2005): T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. PLoS Med, 2:78. https://doi.org/10.1371/journal.pmed.0020078.

      [51] Vlieghe, P., Lisowski V, Martinez J, et al. (2010): Synthetic therapeutic peptides: science and market. Drug Discov. Today 15 (1–2), 40–56. https://doi.org/10.1016/j.drudis.2009.10.009.

      [52] Wallner BP, Gefter ML: (1994): Immunotherapy with T-cell reactive peptides derived from allergens. Allergy, 49:302–308. https://doi.org/10.1111/j.1398-9995.1994.tb02272.x.

      [53] Walsh, G. (2010): Biopharmaceutical benchmarks. Nat. Biotechnol. 28, 917-25. https://doi.org/10.1038/nbt0910-917.

      [54] Wilbur Johnson, Jr. (2013): Safety assessment of palmitoyl oligopeptides ingredients as used in cosmetics. CIR expert panel meeting March 18-21.

      [55] Wilma F. Bergfeld, Donald V. Belsito, and Curtis D. Klaassen et al. (2014): Tentative Report for Panel Review. Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics. Cosmetic Ingredient Review. Accessed online on 27th December 2019.

      [56] Yamashita Y, Sakamoto K. (2015): Role of urocanic acid in the stratum corneum. In: Sakamoto K, editor. Amino acid and peptide at the forefront of cosmetic ingredients. Tokyo, Japan: CMC Research K.K.; 2015. p. 260-72 [Chapter 25].

  • Downloads

  • How to Cite

    Y. Issa, S., & Carmichael, R. (2020). Are synthetic peptides real toxic allergens? a comprehensive literature review and update on therapeutic and adverse toxic immunogenic potentials of peptides -truth or dare. International Journal of Pharmacology and Toxicology, 8(1), 36-40. https://doi.org/10.14419/ijpt.v8i1.30275

    Received date: 2020-01-02

    Accepted date: 2020-02-12

    Published date: 2020-03-06